SCHEMBL4455048

SCHEMBL4455048

Nc1cccc2c(S(=O)(=O)NC3CCc4ccccc43)cccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
NSD2 O96028 8/20 0.52
ALOX5AP P20292 2/20 0.49
FEN1 P39748 2/20 0.49
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HTT P42858 1/20 0.43
CYP1A2 P05177 1/20 0.43
TTR P02766 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4445419 0.93 ALDH1A1 (0.52) CA1CA2NSD2ALDH1A1SMN1; SMN2
SCHEMBL4443056 0.79 CA1 (0.47) CA1CA2ALOX5APFEN1ALDH1A1
SCHEMBL15915670 0.78 CA1 (0.60) CA1CA2ALOX5APFEN1ALDH1A1
SCHEMBL15915716 0.78 CA1 (0.60) CA1CA2ALOX5APFEN1ALDH1A1
SCHEMBL8404960 0.74 ALDH1A1 (0.69) CA1CA2ALDH1A1SMN1; SMN2TSHR
SCHEMBL4759729 0.73 CA1 (1.00) CA1CA2ALDH1A1SMN1; SMN2TSHR
SCHEMBL4443363 0.73 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPK1NPSR1KDM4E
SCHEMBL13660786 0.71 CA1 (0.58) CA1CA2ALOX5APFEN1ALDH1A1
SCHEMBL23093045 0.70 NSD2 (0.55) NSD2KDM4ETTR
SCHEMBL29900502 0.70 NSD2 (0.55) NSD2KDM4ETTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547716-B2 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-06-16 US claimed
US-7547716-B2 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-06-16 US disclosed
EP-1402890-B1 SULFONAMIDE DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2008-01-09 EP disclosed
US-20040234622-A1 Sulfonamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-11-25 US disclosed
EP-1402890-A1 SULFONAMIDE DERIVATIVES Institute of Medicinal Molecular Design, Inc. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040234622-A1 Sulfonamide derivatives PCNA, TOP2A, DDB1 CA1 2328/4885CA2 779/4885NSD2 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.